The FDA accepted REZDIFFRA determined by proof of efficacy from a clinical demo, Trial 1, of 888 patients who had a liver biopsy demonstrating inflammation resulting from NASH with reasonable or Sophisticated liver scarring, but not with cirrhosis of the liver.Some multinational liver societies suggest utilizing the title metabolic dysfunction-link